 |
|
|
|
|
Indiana Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing IndianaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Covance, Inc.
| | | | | Phone: | (317) 467-3700 | | Fax: | (317) 467-7420 | | Year Established: | 1997 | | Ticker: | LH | | Exchange: | NYSE | | Main Contact: | John Ratliff, CEO | | | | Other Contacts: | Jonathan Zung, Group President, Clinical Development
Jonathan Koch, Group President, R&D Laboratories
Herman E. Scholtz, MD, VP & GM, Early Clinical Services
Chris Gegelys, General Counsel
John Gransee, CFO
Honggang Bi, GM, China
Dimitris K. Agrafiotis, PhD, FRSC, Chief Data Officer
Steven Anderson, CSO
| | | | Company Description | Covance is one of the world's largest and most comprehensive drug development services companies with 37 sites in 17 countries and approximately 7,000 employees.
Covance offers development services such as safety assessment, clinical pharmacology, consulting, to late-stage development services that include clinical trial management, central laboratory testing, central diagnostics, and commercializationt.
On Feb. 19, 2015, LabCorp® announced the completion of its acquisition of Covance. At closing, the purchase consideration was valued at $107.19 per Covance share, consisting of $75.76 in cash and 0.2686 LabCorp shares for each Covance share, or an equity value of $6.2 billion and an enterprise value of $5.7 billion. | |
|
|
|
|
|
|
|
